Venus Remedies to launch arthritis drug

Venus Remedies will launch its new drug, ‘Trois’, for treatment of arthritis in June or July to tackle what is predicted to become the “biggest epidemic” in India by 2013

Pharma major Venus Remedies said it will commercially launch its new drug, ‘Trois’, for treatment of arthritis in June or July to tackle what is predicted to become the “biggest epidemic” in India by 2013 with a $672 million market for rheumatoid arthritis drugs.

It also said that it was carrying out research on developing innovative drugs for treating viral diseases and immune system enhancing medicines. “We will launch ‘Trois’ in the month of June or July,” the company’s joint managing director-cum-director research Manu Chaudhary said today.

“This nano technology-based product, Trois, has many advantages, as it has got 178% faster penetration that leads to quick onset of action resulting in enhanced bioavailability, reduction in pain and inflammation associated with arthritis,” Mr Chaudhary said.

This technology is fully developed and the patent for this technology has already been filed and grants are expected soon, she said.

According to a survey, nearly 70% of people above 65 years of age are suffering from arthritis in India and it would become the biggest epidemic of the country by 2013.

The rheumatoid arthritis drug market in India will be more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

About 1% of the world’s population has rheumatoid arthritis. Its market is expected to exceed $23.12 billion by 2015.

Arthritis is one of the most chronic health problems in the world and one of the USA’s most common causes of disability. An estimated 46 million adults in the United States that have arthritis and related conditions could benefit from ‘Trois’.

The Panchkula-based company has also been awarded a Gold Medal under DST-Lockheed Martin India’s Innovation Growth Program-2011 for integrated medicinal research product ‘Trois’.

In the late afternoon, Venus Remedies was trading at around Rs204.50 per share on the Bombay Stock Exchange, 0.07% down from the previous close.

User

Bhopal gas case: Government to abide by SC decision

Law minister says other petitions still pending on punishment to accused and compensation to those affected

New Delhi: The government today said it will abide by the decision of the Supreme Court which dismissed the CBI's curative petition against an earlier judgement of the Court that diluted charges against the accused in the Bhopal gas disaster case.

"We will go by the decision of the Supreme Court," law minister Veerappa Moily told journalists. "After this matter came up, the group of ministers in its due wisdom decided to go for the curative petition. After obtaining the opinion from the learned attorney general of India, we had filed the curative petition and the Supreme Court in its wisdom has dismissed it. We will abide by the decision."

Asked about the compensation component as well as punishment to the accused, the minister said he still has to go through the judgement and he pointed out that there are other petitions also which are yet to be disposed, PTI reports.

Mr Moily, however, made it clear that the compensation component was not linked with the curative petition and was a separate issue. He said that the compensation issue was still open. "We have given more compensation. We have released more money from the Government of India," the minister said.
 
The CBI and the Madhya Pradesh government filed the curative petitions after a public outcry over what was considered as a mild punishment for the gas tragedy in December 1984 that claimed over 15,000 lives and left several thousands maimed.

User

SC dismisses CBI’s curative petition on Bhopal gas tragedy

Court says investigative agency and Madhya Pradesh government failed to explain satisfactorily the need for such a plea after 14 years

New Delhi: In an apparent setback to the campaign by those seeking stringent punishment for the accused in the Bhopal gas disaster, the Supreme Court today dismissed the curative petition by the Central Bureau of Investigation (CBI) against an earlier apex court judgement that apparently diluted charges against the accused.

A five-judge constitutional bench headed by chief justice SH Kapadia, however, left a window of opportunity open, saying that its order would not influence the pending proceedings before the Sessions Court against the chief judicial magistrate's judgement awarding two years sentence to the accused, including Union Carbide India chairman Keshub Mahindra.

The judges said the CBI and the Madhya Pradesh government had failed to give a satisfactory explanation on filing the curative petition after a lapse of 14 years. The other judges on the bench were Altamas Kabir, RV Raveendran, B Sudershan Reddy and Aftab Alam, PTI reports.

The CBI and the Madhya Pradesh government filed the curative petition after a public outcry over what was considered as a mild punishment for the gas tragedy that claimed over 15,000 lives in December 1984 and maimed several thousands.

In 1996, a two-judge bench of the Supreme Court, headed by then chief justice AH Ahmadi, diluted the charges against the accused, avoiding section 304 Part II of the Indian Penal Code that provides for a maximum of 10 years imprisonment and instead applying section 304(A) for rash and negligent act that has a maximum punishment of only two years.

The CBI and the Madhya Pradesh government have filed revision petitions before the Sessions Court and against the judgement of the chief judicial magistrate, Bhopal, which had awarded the two years jail term for various accused.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)